Preprint
Cabotegravir is not associated with weight gain in HIV-uninfected individuals in HPTN 077
Registro en:
LANDOVITZ, Raphael J. et al. Cabotegravir is not associated with weight gain in HIV-uninfected Individuals in HPTN 077. Clinical Infectious Diseases, p. 1-16, May 2019.
1058-4838
10.1093/cid/ciz439
Autor
Landovitz, Raphael J.
Zangeneh, Sahar Z.
Chau, Gordon
Grinsztejn, Beatriz
Eron, Joseph J.
Dawood, Halima
Magnus, Manya
Liu, Albert Y.
Panchia, Ravindre
Hosseinipour, Mina C.
Kofron, Ryan
Margolis, David A.
Rinehart, Alex
Adeyeye, Adeola
Burns, David
McCauley, Marybeth
Cohen, Myron S.
Currier, Judith S.
Resumen
Studies in HIV-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. HPTN 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups. 2020-05-25